HealthcareNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 1965040FTRE stock profile & AI dashboard →

13F Pro Quality Score

45.7/100

Rank #1,862 of 2,960 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

20.2/100

Profitability

39.5/100

Balance Sheet

26.2/100

Earnings Quality

88.0/100

Free Cash Flow

48.5/100

Institutional Flow

19.9/100

Revenue Scale

67.7/100

Dilution Risk

34.5/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

FTRE Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Fortrea Holdings Inc. (FTRE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FTRE at 45.7/100 on a 32-signal composite quality model, placing it at rank #1,862 of 2,960 stocks — the bottom half of the AI-ranked universe. FTRE scores in the top quartile across earnings quality (88.0). Areas of concern include institutional flow (19.9) and revenue growth (20.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 34.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Fortrea Holdings Inc. reports quarterly revenue of $678.2M, net income of $-13.2M, an operating margin of 2.2%. Top institutional holders of FTRE by reported 13-F value include BlackRock, GOLDMAN SACHS GROUP, Sessa Capital IM, L.P., based on the most recent SEC filings. FTRE trades on the Nasdaq exchange and files with the SEC under CIK 1965040. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FTRE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Fortrea Holdings Inc. directly from SEC EDGAR. Fortrea Holdings Inc.'s 13F Pro composite quality score has ranged between 26 and 46 since 2024, currently 45.7 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

Fun facts about Fortrea Holdings Inc.

Quirks, history, and lore behind FTRE — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. healthcare company · mid-cap · listed on Nasdaq · headquartered in North Carolina.
  • 2
    The Numbers
    Generates roughly $3 billion in annual revenue and operates across more than 90 countries — because drug pipelines don't respect borders.
  • 3
    The History
    Spun off from Labcorp in 2023, it became an independent publicly traded company carrying decades of clinical research heritage into a new chapter.
  • 4
    The Secret
    It doesn't make drugs — it tests them for everyone else, running clinical trials and laboratory services that help pharma and biotech companies get their products approved.
  • 5
    The Lore
    With roughly 19,000 employees worldwide, it is one of the largest contract research organizations (CROs) on the planet — the unsung backbone of modern medicine.
  • 6
    The Giveaway
    A Labcorp spinoff that kept the clinical trials business, traded under the ticker FTRE, and named itself something that sounds like a Latin word for strength.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$678.2M

Net Income

Q2 2026

$-13.2M

Free Cash Flow

Q2 2026

$19.9M

Operating Margin

Q2 2026

2.2%

ROIC

Q2 2026

3.8%

D/E Ratio

Q2 2026

2.01

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+1.0% YoY
$2.72BFY 2025
FY22 $2.84BFY23 $2.84BFY24 $2.70BFY25 $2.72B

Net Income

-200.2% YoY
$-986.2MFY 2025
FY22 $186.2MFY23 $-25.2MFY24 $-328.5MFY25 $-986.2M

Operating Income

-439.0% YoY
$-872.6MFY 2025
FY22 $187.1MFY23 $32.0MFY24 $-161.9MFY25 $-872.6M

EPS (Diluted)

-194.6% YoY
$-10.81FY 2025
FY22 $2.09FY23 $-0.29FY24 $-3.67FY25 $-10.81

Total Assets

-24.1% YoY
$2.72BFY 2025
FY22 $4.29BFY23 $4.33BFY24 $3.58BFY25 $2.72B

Total Debt

-6.4% YoY
$1.05BFY 2025
FY22 $0.00FY23 $1.59BFY24 $1.12BFY25 $1.05B

Op. Cash Flow

-56.8% YoY
$113.5MFY 2025
FY22 $82.7MFY23 $168.4MFY24 $262.8MFY25 $113.5M

Free Cash Flow

-62.8% YoY
$88.3MFY 2025
FY22 $28.3MFY23 $128.1MFY24 $237.3MFY25 $88.3M

Get alerted when FTRE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Fortrea Holdings Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of FTRE

Companies Similar to FTRE

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

43
AI score
Similar quality profile · 6 shared holders
SRPT

Sarepta Therapeutics, Inc.

32
AI score
Similar quality profile · 12 shared holders
TDOC

Teladoc Health, Inc.

40
AI score
Similar quality profile · 5 shared holders
ELAN

Elanco Animal Health Inc

50
AI score
Similar quality profile · 5 shared holders
CC

Chemours Co

44
AI score
Similar quality profile · 9 shared holders
NEOG

NEOGEN CORP

42
AI score
Similar quality profile · 6 shared holders
TNDM

TANDEM DIABETES CARE INC

40
AI score
Similar quality profile · 13 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put FTRE on your watchlist

Track score changes the day Fortrea Holdings Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is FTRE a good stock to buy?

13F Pro's AI-powered analysis of Fortrea Holdings Inc. (FTRE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FTRE are available on the FTRE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FTRE is classified as a small company.

Which hedge funds own FTRE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FTRE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Fortrea Holdings Inc.'s investment landscape.